Share Article

Augmenix, UK Ltd. Launches New UK SpaceOAR Hydrogel Website

Request More Information
Summary of Article

Augmenix has launched a dedicated UK website to support the growing number of clinicians and patients who are using SpaceOAR® hydrogel to help reduce unnecessary and life-changing side-effects from prostate cancer radiotherapy.

Throughout the UK over 45,000 men are diagnosed with prostate cancer every year.1 This means about 1 in 8 men will get prostate cancer at some point in their lives.2 Many patients are treated successfully with different forms of radiotherapy, but there are known side-effects such as rectal bleeding, rectal pain, impaired sexual function, and faecal and urinary incontinence that result from radiation damage to the organs and tissues surrounding the prostate. SpaceOAR Hydrogel is a soft, implantable gel which is placed with a minimally invasive procedure and is clinically proven to reduce the short and long-term side-effects of radiation exposure.

“The development of a UK centric website provides doctors in the UK and Ireland more clinical information, materials and tools on both the application and benefits of SpaceOAR. Helping them make a difference to men undergoing radiotherapy.” said Stephen McGill, Vice President and General Manager of Augmenix International.

“This website will also provide patients with resources and information to support their journey with SpaceOAR hydrogel during radiotherapy. Due to the high level of media interest on hydrogel spacing, we have invested in building an online ‘find a hospital tool’. This online tool is integrated into the website and will allow patients to conduct their own research and search for private and public hospitals who have setup SpaceOAR implantation services.”

1.    Prostate Cancer UK. 2018. About Prostate Cancer. [ONLINE] Available at: [Accessed 15 October 2018].
2.     Cancer Research UK. 2018. Prostate Cancer Statistics. [ONLINE] Available at: [Accessed 15 October 2018].